Breaks Categories: News

FridayDec 18, 2020 9:45 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Commencement, Pricing of Underwritten Public Offering

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the commencement and pricing of an underwritten public offering. The offering consists of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share. VistaGen expects $100 million in gross proceeds from the offering, before underwriting discounts, commissions and estimated offering expenses. Subject to…

Continue Reading

FridayDec 18, 2020 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company also intends to discuss its planned Phase 2 Berubicin clinical trial on the call slated for Friday, December 18, 2020 at 8:30 AM ET. Interested parties may access the call by dialing (800) 226-2188 (domestic) or (602) 563-8462 (international)…

Continue Reading

ThursdayDec 17, 2020 12:17 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces NeuroCap for Children, Enters Pediatric Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has launched its next-generation, disposable EEG cap, NeuroCap(TM) in a children’s size, making the innovative product available for use in the U.S. pediatric market. The smaller NeuroCap headset is designed to overcome common challenges that arise when conducting an electroencephalogram (“EEG”), such as measuring and marking the patient’s head, and following sanitation protocols. The pediatric NeuroCap also addresses the need for comfort, speed and reliability within the pediatric population. BRSF’s disposable, pre-gelled NeuroCap features 19 active EEG channels and 22 electrodes and can be quickly, easily and accurately applied by any…

Continue Reading

ThursdayDec 17, 2020 11:41 am

BioMedNewsBreaks – Delcath Systems Inc. (NASDAQ: DCTH) Secures $22.2M in Underwritten Public Offering

Delcath Systems (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, has closed an underwritten public offering of 1,679,031 shares of its common stock, including 219,004 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Delcath Systems secured approximately $22.2 million in gross proceeds with each of the shares sold at the public offering price of $13.25. The company intends to use the net proceeds for completion of its FOCUS clinical trial for patients with hepatic dominant ocular melanoma, preparation of…

Continue Reading

ThursdayDec 17, 2020 10:46 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Proprietary Systems to be Utilized at Leading Specialty, Emergency Veterinary Care Hospitals

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has finalized agreements to place its exclusive MiQLab(TM) systems at two specialty and emergency veterinary hospitals as part of the company’s Early Access Program (“EAP”); the company anticipates placing the systems in early 2021. The two practices are Veterinary Specialty Hospital (“VSH”) of Palm Beach Gardens, Florida, and Denver Animal Emergency in Denver, North Carolina. According to the agreement, the two leading hospitals will evaluate MiQLab-generated data, which is generated quickly, against traditional culture and sensitivity testing, which can take up to five days…

Continue Reading

ThursdayDec 17, 2020 9:18 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval of IND Application for Brain Cancer Drug Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced that it has received US Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application on its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). This approval signifies a crucial step for the company in launching a potentially pivotal trial to investigate the efficacy of Berubicin in adults with GBM who have been unsuccessful with first-line therapy. In addition, following recent correspondence with the FDA, the…

Continue Reading

WednesdayDec 16, 2020 12:17 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on ‘Want Money Got Money’ Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and skills of the world’s most brilliant and interesting start-up founders and investors. During the podcast, Climaco talked about recent research conducted by CNSP founder Dr. Waldemar Priebe that studies the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. In addition, Climaco discussed CNS Pharmaceuticals’ lead drug candidate, Berubicin. The drug is being proposed as a treatment for GBM. A Phase I clinical…

Continue Reading

WednesdayDec 16, 2020 8:30 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Closes IPO, Exercises Option to Purchase Additional Shares

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, has announced the closing of its initial public offering (“IPO”). The IPO consisted of a total of 4,025,000 shares — 3,500,000 shares of common stock combined with 525,000 additional shares made available through the exercise of the underwriters’ option to purchase additional common stock shared. All the shares were offered at the price of $6 per share, and resulted in $24.15 million for the company, before underwiring discounts, commissions and other related expenses were deducted.…

Continue Reading

TuesdayDec 15, 2020 2:38 pm

BioMedNewsBreaks – Way2Grow (‘W2G’) Biopharma Company Announces Entry into Cannabis Productivity, Plans for Psychedelic Research and Development

Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, today announced its entry into the productivity phase of cannabis cultivation, micropropagation and extraction. The company also announced its preparation of a Health Canada application towards psychedelic research and development for a medicinal mushroom (Psilocybe semilanceata) Dealer Licence and a Section 56 Exemption for use of psilocybin production and extraction for planned preclinical research under scientific purposes, per the Controlled Drugs and Substances Act (the “CDSA”). According to the update, W2G has secured approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic…

Continue Reading

TuesdayDec 15, 2020 12:12 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Launches Regulation A+ Offering

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has launched a Regulation A+ equity crowd-funding campaign. The announcement follows the qualification by the U.S. Securities and Exchange Commission of BRSF’s Form 1-A offering. The intended purpose of the offering is to provide both accredited and non-accredited potential investors an opportunity to support the company in its efforts to more fully introduce its proprietary technologies to the neurology market. Through its Reg A+ offering, Brain Scientific will sell units at $9 each, with a minimum investment of $500. The units are comprised of five  shares of common stock and one…

Continue Reading